Why is Takeda’s Orzeyful approval for narcolepsy type 1 important?

Takeda’s FDA approval of oveporexton, to be marketed as Orzeyful, gives narcolepsy type 1 a first-in-class treatment that FiercePharma said addresses the disease’s root cause. The approval shifts attention from Takeda’s earlier OX2R agonist setbacks to whether it can execute commercially with payers, access, and physician uptake.